risankizumab vs SPY003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
risankizumab · Skyrizi
Marketed by AbbVie and partners
NCT03398148 · Phase 2/3 · completed
Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.
Next expected readout: August 2027 · NCT06880744 (registry estimate)
Reported efficacy
clinical remission + endoscopic improvement met (met)
Result source: INSPIRE/COMMAND
SPY003
Developed by Spyre Therapeutics
NCT07012395 · Phase 2 · recruiting
This was a randomized, quadruple-masked Phase 2 trial with 645 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-08. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Next expected readout: June 2027 · NCT07012395 (registry estimate)
Reported efficacy
Part A: Change in Robarts Histopathology Index (RHI) (Week 12); Part B: Percentage of participants with clinical remission (Week 12): Part A primary endpoint (week 12): Robarts Histopathology Index reduced 10.0 points from baseline (p<0.0001) (Spyre, 2026-09-08). (met)
Result source: NCT07012395
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | risankizumab | SPY003 |
|---|---|---|
| Clinical remission (induction) | 20.3% vs 6.2%+14.1 vs placeboNCT033981484 other results
| —Not reported |
| Clinical remission (maintenance) | —Trial running · NCT03398135 | —Not reported |
| Clinical response (induction) | 64.3% vs 35.7%+28.6 vs placeboNCT033981489 other results
| —Not reported |
| Endoscopic improvement (induction) | 36.5% vs 12.1%+24.4 vs placeboNCT03398148 | —Not reported |
| Corticosteroid-free remission (maintenance) | —Trial running · NCT03398135 | —Not reported |
Clinical remission (induction)
- risankizumab
- 20.3% vs 6.2%+14.1 vs placeboNCT03398148
4 other results
- 12.4% vs 1.7% NCT03398148
- 9.8% vs 1.7% NCT03398148
- 10.3% vs 1.7% NCT03398148
- 11.5% vs 1.7% NCT03398148
- SPY003
- —Not reported
Clinical remission (maintenance)
- risankizumab
- —Trial running · NCT03398135
- SPY003
- —Not reported
Clinical response (induction)
- risankizumab
- 64.3% vs 35.7%+28.6 vs placeboNCT03398148
9 other results
- 52.2% vs 30.5% NCT03398148
- 46.2% vs 20% NCT03398148
- 43.5% vs 25% NCT03398148
- 45.9% vs 20% NCT03398148
- 45.9% vs 25% NCT03398148
- 53.4% vs 20% NCT03398148
- 37.9% vs 25% NCT03398148
- 42.6% vs 20% NCT03398148
- 32.8% vs 25% NCT03398148
- SPY003
- —Not reported
Endoscopic improvement (induction)
- risankizumab
- 36.5% vs 12.1%+24.4 vs placeboNCT03398148
- SPY003
- —Not reported
Corticosteroid-free remission (maintenance)
- risankizumab
- —Trial running · NCT03398135
- SPY003
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. risankizumab: 4 of 4 rows · SPY003: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | risankizumab |
|---|---|
| Dropout rate | 4.9%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 10.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.8%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Discontinued due to AEs | 3.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results—1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 0%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 3.3%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Serious AEs | 6.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 13 more results2.6%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.5%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.3%1200 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.9%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1.4%360 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.5%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 5.6%180 mg SC NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.6%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 —1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 7.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 2.7%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 8.3%1800 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 9.7%600 mg IV NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
| Most frequent reported AEs | 1200 mg IV colitis ulcerative 4.9% (placebo 8.5%) headache 4.9% (placebo 5.1%) nasopharyngitis 4.9% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 show 12 more results1200 mg IV covid-19 4.6% (placebo 0%) anaemia 3.2% (placebo 3.4%) headache 2.9% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.9% (placebo 0%) headache 2.9% (placebo 5.1%) anaemia 1.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1200 mg IV covid-19 5.7% (placebo 0%) anaemia 2.9% (placebo 3.4%) colitis ulcerative 1.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC nasopharyngitis 8.5% (placebo 6.8%) headache 7% (placebo 5.1%) colitis ulcerative 4.2% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 360 mg SC anaemia 8.5% (placebo 3.4%) covid-19 8.5% (placebo 0%) headache 8.5% (placebo 5.1%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC headache 2.8% (placebo 5.1%) anaemia 1.4% (placebo 3.4%) nasopharyngitis 1.4% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 180 mg SC covid-19 5.6% (placebo 0%) colitis ulcerative 4.2% (placebo 8.5%) anaemia 2.8% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 8.6% (placebo 6.8%) headache 6.9% (placebo 5.1%) anaemia 1.7% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 7% (placebo 6.8%) headache 6.5% (placebo 5.1%) anaemia 3.5% (placebo 3.4%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV nasopharyngitis 10.8% (placebo 6.8%) anaemia 2.7% (placebo 3.4%) colitis ulcerative 2.7% (placebo 8.5%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 1800 mg IV dry skin 5.6% (placebo 0%) headache 5.6% (placebo 5.1%) nasopharyngitis 5.6% (placebo 6.8%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 600 mg IV nasopharyngitis 8.1% (placebo 6.8%) bronchitis 6.5% (placebo 0%) dry skin 3.2% (placebo 0%) NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
risankizumab
show 4 more results
show 3 more results
show 9 more results
show 4 more results
show 3 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
show 3 more results
show 4 more results
show 3 more results
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: risankizumab's landscape · SPY003's landscape